So which are the 5 fastest growing biotech companies in the US? Keep up reading and we present you with three companies out of the top 5, based on Insider Monkey’s latest article. Novavax, Inc ranks five on the list. As of 2018 the total revenue was $34.2 million, while in 2019 it was $18.6 million. The Gaithersburg, Maryland-based company has 522 employees. The company manufactures vaccine candidates using recombinant nanoparticle vaccine technology to respond to both known and emerging diseases. The company’s major target is to develop vaccines against infectious diseases, such as Ebola, respiratory syncytial virus (RSV), seasonal influenza and pandemic influenza. It’s also involved in developing immune-stimulating saponin-based adjuvants. Moreover, Novavax is developing a vaccine against COVID-19, and its candidate is in the preclinical stage. Novavax and Takeda Pharmaceutical Company Limited cooperate to develop, manufacture and sell NVX-CoV2373, a COVID-19 vaccine candidate. According to Insider Monkey’s investigation, the candidate showed 89.3% efficacy in the clinical trial in the United Kingdom. Novavax is followed by CureVac N.V. on the fourth spot with having a total revenue of $12.9 million in 2018, and $17.4 million of revenue in 2019. The company has 500 employees and is headquartered in Tuebingen, Germany. The company was launched only in 2000, and this biopharmaceutical company operates in developing messenger ribonucleic acid(mRNA) vaccines and drugs for curing rare diseases, cancer and infectious diseases. It has three main operating fields:protein-based therapy, prophylactic vaccines and cancer immunotherapy. The company’s main clinical programs are dedicated to ‘CV8102’ for curing four types of solid tumors, and ‘CV7202’ for potential vaccination against rabies. Also, as several other companies, CureVac N.V. started to develop its own vaccine against COVID-19, which is in Phase III trial. Seagen Inc. ranks second on the list with having a total revenue of $654.7 million in 2018, and $916 million of revenue in 2019. The company has 1,605 employees and is headquartered in Bothell, Washington. Seagen was established in 1997 originally as Seattle Genetics, Inc. The company mainly concentrates on conjugating drugs and antibodies to fight against cancer. One of their main product family comprises ADCETRIS for curing Hodgkin lymphoma or CD30 CD30-positive T-cell lymphomas. Seagen is also involved in developing new cures for blood-related cancers and solid tumors. The company has cooperative agreements with Millennium, Celldex Therapeutics, PSMA Development Company LLC, Genentech, Inc., and Genmab A/S. For more information about fastest growing biotech companies in the US, please click and jump to the entire article.